Dhuwit awis perusahaan Revolution Medicines Corp (RVMD)

Logo grafis Revolution Medicines Inc (RVMD)

Revolution Medicines leverages its authority in targeted oncology to develop drugs combating the RAS pathway for patients with limited options. The cash accumulation chart confirms financial stability, where the latest parameter stands at 3.66. Efficiency is maintained through the strategic outsourcing of drug synthesis and early-stage testing to external partners, which completely mitigates operational dependency risks.

RVMD - Aset likuid perusahaan RevMed ing rentang 04.07.2022 - 21.11.2026

RevMed (RVMD) - rincian metrik lan laporan keuangan

Pambiji fundamental:RVMD revmed.com
Produk mawa merek Revolution Medicines Inc

This indicator captures the absolute volume of liquid assets, allowing for the real-time tracking of cash reserve accumulation or burn rates. For Revolution Medicines (RVMD), this metric confirms the ability to fund high-tech laboratories and audits of partner factories, while the company's cash on hand serves as a marker of financial stability in the face of operating expenses.

Pesaing Revolution Medicines

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Volume dana dhuwit perusahaan AAPG (ascentage.com)|CG Oncology Inc (CGON) - Cadangan dhuwit perusahaan|URGN - Dana dhuwit perusahaan|Bicara Bio - Gunggung dana dhuwit perusahaan|PSNL: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan ERAS|Dhuwit awis perusahaan DCTH|Cadangan dhuwit perusahaan Y-mAbs Therapeutics Inc YMAB|Volume dana dhuwit perusahaan AURA|CADL (Candel Therapeutics, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan Accuray Inc ARAY|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan